Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Safety profile in PIONEER trials: Nausea: 11% to 20% (dose-dependent) Diarrhea: 8% to 11% Vomiting: 5% to 9% Discontinuation due to GI side effects: 4% to 7% The side effect rates are lower than injectable semaglutide at weight-loss doses, likely because the systemic exposure is lower
Tirzepatide Powder stands as the world's first dual-agonist API, simultaneously targeting both GIP and GLP-1 receptors to deliver unprecedented therapeutic outcomes in metabolic disorder management
The most common side effects are nausea, diarrhoea, constipation, vomiting, indigestion and abdominal discomfort
Retatrutides improvements in osteoarthritis pain could help people become more active and maintain results long-term
US$ 28.59
US$ 20.48
US$ 28.03
US$ 24.06
US$ 25.16
US$ 29.90
US$ 27.67
US$ 27.68
